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Dosage of immunosuppressive drugs after transplantation critically determines rejection
and infection episodes. In this study, a global immune function assay was characterized
among controls, dialysis-patients, and transplant-recipients to evaluate its utility for
pharmacodynamic monitoring of immunosuppressive drugs and for predicting infections.
Whole-blood samples were stimulated with anti-CD3/toll-like-receptor (TLR7/8)-agonist
in the presence or absence of drugs and IFN-γ secretion was measured by ELISA.
Additional stimulation-induced cytokines were characterized among T-, B-, and NK-cells
using flow-cytometry. Cytokine-secretion was dominated by IFN-γ, and mainly observed
in CD4, CD8, and NK-cells. Intra-assay variability was low (CV = 10.4 ± 6.2%), whereas
variability over time was high, even in the absence of clinical events (CV= 65.0± 35.7%).
Cyclosporine A, tacrolimus and steroids dose-dependently inhibited IFN-γ secretion,
and reactivity was further reduced when calcineurin inhibitors were combined with
steroids. Moreover, IFN-γ levels significantly differed between controls, dialysis-patients,
and transplant-recipients, with lowest IFN-γ levels early after transplantation (p <
0.001). However, a single test had limited ability to predict infectious episodes. In
conclusion, the assay may have potential for basic pharmacodynamic characterization
of immunosuppressive drugs and their combinations, and for assessing loss of global
immunocompetence after transplantation, but its application to guide drug-dosing and
to predict infectious on an individual basis is limited.
Keywords: immunomonitoring, transplantation, immunosuppression, infection, pharmacodynamics,
pharmacokinetics, T-cell
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INTRODUCTION
Immunosuppressive drug treatment and the development of
new drugs have made significant contributions to improved
outcome and survival of transplanted organs over the last
decades. The net state of immunosuppression in transplant-
recipients is interindividually variable and may be influenced
by the dosage and combination of drugs, but also by age
and other comorbidities. The choice of immunosuppressive
drugs and their dosage influences clinical outcome in that
underimmunosuppression favors rejection episodes and
overimmunosuppression is associated with an increased
incidence of infectious complications. This is particularly
evident in the first months after transplantation, when
immunosuppression is highest. As not all patients develop
clinical complications, assays for monitoring of drug effects
and for predicting infectious complications are needed
for personalized management of immunosuppressive and
antimicrobial drug therapy.
At present, immunosuppressive drugs are either prescribed
in empirically defined dosages or based on determination of
individual drug-levels from blood. As this pharmacokinetic
type of drug-dosing does not take interindividual differences in
drug-susceptibility into account, pharmacodynamic monitoring
of immunosuppressive drug effects on major lymphocyte
populations has been explored as a promising approach
toward individualization of immunosuppressive drug treatment
(1). Pharmacodynamic principles include assessment of the
inhibitory action of drugs on the activity of enzymatic drug-
targets or on transcription factors, on ATP function or on
cytokine induction (2, 3). Disadvantages of these approaches
include requirement of isolated blood cells and use of aqueous
media under non-physiological conditions (3, 4). In this
regard, whole blood assays may be favorable, as little sample
manipulation is involved, and immunosuppressive drugs are
present in clinically relevant concentrations and therefore closely
represent physiological conditions in vivo. This is illustrated in
whole blood samples stimulated with viral or bacterial antigens,
where calcineurin-inhibitors exert a dose-dependent inhibitory
action on intracellular cytokine induction in T-cells (5–7). Based
on the choice of stimuli, these analyses were restricted to T-cells,
and did not provide any information on the inhibitory action of
immunosuppressive drugs on lymphocyte subpopulations of the
innate immune system. This may be of interest, as NK-cell or
Toll-like receptor (TLR) polymorphisms or altered complement
levels were shown to be associated with an increased incidence of
infections (8–10).
The QuantiFERONmonitor assay (Qiagen, Hilden, Germany)
is a novel global immune assay that is based on induction of IFN-
γ from whole blood samples after stimulation with a lyosphere
consisting of a T-cell stimulus (anti-CD3) and a TLR7/8-agonist
(R848). It therefore targets cellular components of both the
Abbreviations: IFN-γ, interferon-γ; TNF-α, tumor necrosis factor α; IL-2,
interleukin 2; CMV, cytomegalovirus; BKPyV, BK polyomavirus; mTOR,mamalian
target of rapamycin; MMF, mycophenolate mofetile; TLR, toll like receptor; IQR,
interquartile range; SD, standard deviation.
adaptive and the innate immune response, although the relative
contribution of these subpopulations toward IFN-γ production
is currently unknown. The assay may hold promise as a tool to
predict infections after transplantation (11, 12). Although IFN-γ
secretion-levels were shown to be lower in transplant-recipients
as compared to controls (11–15), the utility of this assay
for pharmacodynamic analysis of immunosuppressive drugs is
less well-characterized.
This study was carried out to characterize the cytokine-
secreting cellular subpopulations and their dominant cytokine
patterns in response to stimulation with the lyosphere. Moreover,
the assay was used to evaluate its utility for pharmacodynamic
analysis of the inhibitory effect of immunosuppressive drugs
and drug-combinations in vitro and in vivo in clinically relevant
dosages. Finally, immune function of transplant-recipients was
analyzed before and during the first year after transplantation to
assess its utility to predict infectious complications.
MATERIALS AND METHODS
Subjects
Immunocompetent healthy controls were recruited to
characterize cell populations and cytokines after stimulation with
the QuantiFERON monitor assay, to study the inhibitory effect
of immunosuppressive drug and drug-combinations in vitro,
and to study natural diurnal variations in immune-reactivity,
which included whole blood samples collected at five times over
24 h. To analyze the effect of various levels of immunodeficiency
on cellular immune function, immunocompetent controls,
dialysis patients, short-term and long-term transplant-patients
(transplantation < 3 months and more than 1 year ago,
respectively) were recruited. Moreover, renal transplant-patients
were prospectively and consecutively enrolled and immune
function was analyzed before and 1, 3, 6, 12 months after
transplantation and associated with infectious episodes. The
study was approved by the local ethic committee (126/14,
Ärztekammer des Saarlandes), and all individuals gave written
informed consent.
Clinical Outcomes
The occurrence of infections was recorded during the first year
after transplantation based on definitions for use in clinical trials
involving organ transplant-recipients (16). The records of all
patients were screened for bacterial, viral and fungal infections.
Infectious episodes were defined microbiologically or based on
clinical diagnosis and/or response to treatment.
Quantification of Lymphocyte
Subpopulation and Polyclonal Cell
Reactivity
Lymphocytes subsets were identified using cell surface staining of
CD3, CD4, CD8 (T-cells), CD16/CD56 (NK-cells), and CD19 (B-
cells) from whole blood after staining with fluorescently labeled
antibodies (anti-CD3, anti-CD4, anti-CD8, anti-CD16/56, anti-
CD19, all from BD) for 30min at room temperature as described
before (7, 17). Samples were analyzed on a FACS Canto II using
DIVA Software (BD).
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Stimulation and Quantitation of Polyclonal
Cell Reactivity
Heparinized blood samples were polyclonally stimulated using
the QuantiFERON monitor assay (a lyopsphere containing anti-
CD3 antibodies and the TLR7/8 agonist R848) for 20 h at
37◦C at 5% CO2 according to the manufacturer’s instructions
(Qiagen, Hilden, Germany). Thereafter, cell-free supernatants
were frozen at −20◦C, and IFN-γ in the supernatant was
quantified by ELISA. Replicates or longitudinal samples of
one individual were analyzed together on one ELISA plate. In
addition, blood samples were stimulated with the lyosphere
or with 2.5µg/ml Staphylococcus aureus enterotoxin B (SEB)
for intracellular cytokine staining. Samples were stimulated
for 16 h at 37◦C, before adding 10µg/ml brefeldin A. Four
hours later, cells were treated with 2mM EDTA for 15min.
Thereafter, samples were treated with lysing solution (BD).
Fixed cells were washed with FACS buffer (PBS-5%FCS-
0.5%BSA-0.07%NaN3) and subsequently treated with 0.1%
saponin for 10min. The surface markers for T-, B-, and NK-
cells (CD3, CD4, CD8, CD19, CD16/56), CD69 as activation
marker, and cytokines (IFN-γ, IL-2, TNF-α, IL-4, IL-17) were
stained with fluorescent antibodies (all from BD) and analyzed
by flow-cytometry.
Quantification of the Immunosuppressive
Effect of Calcineurin Inhibitors and
Steroids in vitro
Heparinized blood from 10 immunocompetent individuals was
preincubated for 2 h with increasing doses of methylprednisolone
(10, 100, 1,000 ng/ml), cyclosporine A (0, 41, 123.4, 370.3,
1111, 3333 ng/ml), and tacrolimus (0, 2.47, 7.4, 22.2, 66.6,
200 ng/ml) individually and in combination (370.3 ng/ml
cyclosporine A+100 ng/ml methylprednisolone; 22.2 ng/ml
tacrolimus+100 ng/ml methylprednisolone). Thereafter, cells
were stimulated with the lyosphere and IFN-γ secretion was
analyzed by ELISA.
Determination of Endogenous Cortisol
Levels
Cortisol levels were determined from plasma samples by the
central laboratory at Saarland University Medical center
using a solid-phase radioimmunoassay (Ciba Corning,
Berlin, Germany).
Statistical Analyses
Statistical analyses were performed with the GraphPad Prism
Version 5.03. Nonparametric analyses from two or more groups
of non-paired samples were performed using the Mann-Whitney
or Kruskall-Wallis-test, analyses from paired samples were done
using the Friedman test with Dunn’s post-test. The repeated
measures ANOVA with Tukey’s post-test was performed for
paired analyses of parametric values. Correlations were analyzed
according to Spearman.
RESULTS
CD4 T-Cells, CD8 T-Cells, and NK-Cells as
Main Populations Producing Interferon-γ
After Polyclonal Stimulation With Anti-CD3
and a TLR7/8 Agonist
To determine the cells that produce IFN-γ after stimulation
using the QuantiFERON monitor assay, whole blood from
14 immunocompetent individuals was stimulated for 24 h and
cytokine-producing cell subpopulations were determined using
flow-cytometry. IFN-γ secretion into the supernatant by ELISA
was determined in parallel, which showed a large interindividual
variability with median IFN-γ levels of 792.4 IU/ml (IQR 72.7-
1200 IU/ml, Figure 1A). Flow-cytometric analysis identified
CD4 and CD8 T-cells and NK-cells as the main populations
producing IFN-γ, whereas IFN-γ expression in B-cells was
negligible (Figure 1B). Accordingly, IFN-γ secretion-levels from
the supernatant strongly correlated not only with the number
of IFN-γ-producing lymphocytes, but also with the number of
cytokine-producing CD4, CD8, and NK-cells (Figure 1C).
We also investigated other cytokines with important functions
in the cellular immune response. After simultaneous staining of
IFN-γ, IL-2 and TNF-α, IFN-γ was by far the most dominant
cytokine produced by both CD4 and CD8 T-cells (supporting
Figure S1A). Most cells produced IFN-γ only, whereas only
low percentages of cells expressed TNF-α or IL-2 alone or in
combination with IFN-γ. Apart from T-cells, NK-cells were also
stained for expression of IFN-γ and TNF-α. As with T-cells, NK-
cells predominantly produced IFN-γ only (Figure S1B). Among
CD4 and CD8 T-cells, the percentage of IFN-γ expressing T-
cell populations was further compared with cells expressing IL-
4 or IL-17. As shown in Figure S1C, CD4 T-cells producing
IFN-γ predominated, followed by Th2 and Th17 cells (p
< 0.0001). A similar distribution of IFN-γ, IL-4 and IL-17
expressing cells were found among CD8 T-cells. Taken together,
although the lyosphere induced a variety of cytokines, IFN-γ was
predominantly secreted by all tested cell populations.
Natural Diurnal Variation in IFN-γ
Production
As even immunocompetent individuals show diurnal variations
in endogenous cortisol levels, potential natural variations in
cell function in the absence of iatrogenic immunosuppression
was studied in 6 immunocompetent individuals over a time
period of 24 h. In each individual, 6 blood samples were
drawn (8:00 a.m., 12:48 p.m., 5:36 p.m., 10:24 p.m., 3:12 a.m.,
and 08:00 a.m. at the following day), and stimulated with the
lyosphere. Differential blood counts were determined in parallel.
When quantifying themajor lymphocyte subpopulations, diurnal
dynamics of CD4 T-cells, CD8 T-cells and B-cells were similar,
with cell counts being lowest during the day and highest
at night (Figure 2A). In contrast, NK-cells showed different
kinetics with stronger variations during the 24 h period and
an overall decrease in measurable cell numbers from 1 day
to the other (Figure 2A). Interestingly, IFN-γ levels were
highest between evening and early morning hours (Figure 2B).
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FIGURE 1 | CD4 T-cells, CD8 T-cells and NK-cells as main populations producing interferon-γ after polyclonal stimulation with the lyosphere. Whole blood samples
from 14 healthy controls (31.8 ± 7.7 years of age, 10 females) were stimulated for 20 h with the lyosphere and (A) interferon-γ (IFN-γ) was analyzed from the
supernatant. (B) In parallel, IFN-γ producing cell populations were identified and quantified after stimulation and intracellular cytokine staining. Absolute numbers of
IFN-γ producing cells were based on flow-cytometric analyses and differential blood counts. (C) The number of IFN-γ producing lymphocytes and lymphocyte
subpopulations was correlated with IFN-γ release into the supernatant. Correlations were calculated according to Spearman.
This not only followed dynamics of the major lymphocyte
subpopulations but also inversely correlated with endogenous
cortisol levels (Figure 2C). Together this shows that IFN-γ
secretion was highest during night hours and was influenced
by diurnal variations in lymphocyte numbers and endogenous
cortisol levels.
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FIGURE 2 | Diurnal variation in lymphocyte numbers and IFN-γ secretion. Diurnal variation of lymphocyte subpopulations in peripheral blood of healthy controls (n =
6) was determined over 24 h at 8:00 a.m., 12:48 p.m., 5:36 p.m., 10:24 p.m., 3:12 a.m. and the following day at 8:00 a.m. All individuals had a regular day-night
rhythm. Shown are the differences in absolute cell numbers of (A) CD4 T-cells, CD8 T-cells, B-cells, and NK-cells and (B) in levels of IFN-γ and (C) cortisol at each
time point in relation to the daily mean that was calculated from all values analyzed over the 24 h-time period (0 on the y-axis). A differential blood count to calculate
absolute values was missing in one individual at 12:48 p.m. The variance at each time point with respect to this 24 h-mean is expressed as mean ± standard error of
the mean. Statistical analysis was performed using the repeated measures ANOVA with Tukey’s post-test.
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FIGURE 3 | Dynamics of polyclonal T-cell functionality in asymptomatic individuals. Blood samples from healthy controls (n = 10; 53.4 ± 20.6 years of age, 6 females)
were recruited and (A) three replicates of the same samples were stimulated in parallel and IFN-γ was determined from the supernatants. (B) Blood samples from 13
healthy controls (32.1 ± 7.9 years of age, 9 females), 16 hemodialysis patients (67.4 ± 10.9 years of age, 6 females), and 16 long-term transplant-recipients (56.4 ±
14.5 years of age, 6 females) were collected over time (3 samples per person, 35 (IQR 34) days between each time point), and stimulation-induced IFN-γ was
determined from the supernatants.
Dynamics of T-Cell Functionality Over Time
in the Absence of Apparent Clinical
Symptoms
To assess the intra-assay variability, three independent
stimulatory reactions were performed from the same blood
samples of ten healthy controls. IFN-γ levels showed a low inter-
assay variability with a coefficient of variation (CV) of 10.4±6.2%
(Figure 3A). To investigate the inter-assay variability, blood
samples from 13 healthy individuals, 16 dialysis patients and 16
long-term transplant-patients who were apparently healthy were
stimulated with the lyosphere at three different time points at a
median of 35 (IQR 34) days apart from each other. Interestingly,
despite absence of apparent clinical symptoms, cytokine levels
determined from the supernatants within one individual showed
a considerably strong variation over time in all groups with a
similarly high CV of 65.0 ± 35.7% in all groups (Figure 3B, 64.1
± 49.2% for controls, 68.8 ± 34.9% for hemodialysis patients
and 62.0± 23.4% for long-term transplant-recipients).
Strong Effect of Immunosuppressive Drugs
on Stimulation-Induced IFN-γ Secretion in
vitro
To analyze the influence of immunosuppressive drugs on cell
functionality in vitro, blood samples from 10 immunocompetent
controls were pre-treated for 2 h with increasing dosages of
cyclosporine A, tacrolimus and methylprednisolone before
stimulation with the lyosphere (Figure 4). As compared to
samples incubated in the absence of drugs (mock), all three
drugs led to a strong dose-dependent inhibition in IFN-γ
secretion (Figure 4A). This immune reactivity was further
reduced, when cyclosporine A or tacrolimus were combined
with methylprednisolone (Figure 4B). While 367 ng/ml
cyclosporine A treatment led to a decrease in IFN-γ secretion
by 57.1%, the combination with methylprednisolone led to
a further decrease (by 75.6%). Likewise, median secretion
was reduced by 62% with 22.2 ng/ml tacrolimus and further
decreased when combined with steroids (by 83.3%). Thus, both
cyclosporine A and tacrolimus show a synergistic inhibitory
action with steroids which can be analyzed directly from whole
blood in vitro.
IFN-γ Secretion Is Associated With the
Level of Immunodeficiency in Patient
Samples but Does Not Predict Infections
on an Individual Basis
To characterize test performance in patients ex vivo, cross-
sectional analyses of samples from 51 controls and from patients
with different levels of immunodeficiency was performed [71
dialysis patients (67 hemodialysis, 4 continuous ambulatory
peritoneal dialysis), 44 short-term and 61 long-term transplant-
patients]. The demographic and clinical characteristics are
shown in Table S1. As expected, immunocompetent controls had
highest secretion-levels of IFN-γ (median 303.6 IU/ml), whereas
median levels were significantly lower in immunocompromized
patients (Figure 5A, p < 0.001). Among patients, short-term
transplant-patients had lowest IFN-γ secretion-levels (median
12.0 IU/ml), whereas long-term transplant-recipients reached
similar median levels (118.9 IU/ml) as dialysis patients prior
to transplantation (104.9 IU/ml). As most transplant recipients
received tacrolimus as part of their immunosuppressive drug
regimen, the immune function of these patients was analyzed
in relation to tacrolimus trough levels. Short term and long-
term transplant recipients differed in median tacrolimus trough
levels [8.5 (IQR 7.2–10.6) ng/mL vs. 6.2 (IQR 4.7–7.3) ng/mL,
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FIGURE 4 | Decreasing effect of immunosuppressive drugs on stimulation-induced IFN-γ secretion in vitro. (A) Whole blood samples of ten healthy individuals (35.3 ±
12.3 years of age, 7 females) were stimulated with the lyosphere in the absence (mock) or presence of increasing dosages of cyclosporine A, tacrolimus or
methylprednisolone, and IFN-γ was determined from the supernatants. Samples were pre-incubated with the drugs for 2 h prior to stimulation. Absolute levels of
IFN-γ are displayed. Bold dots represent the medians connected by lines. (B) Blood samples were stimulated in the absence of immunosuppressive drugs (mock) or
high dose methylprednisolone (MP, 1,000 ng/ml), cyclosporine A (CyA, 367 ng/ml) or tacrolimus (Tac, 22 ng/ml) as well as respective combinations. Normalized values
are displayed. The level of IFN-γ in mock stimulated samples was set to 100%. Bold dots represent the medians connected by lines. Statistical analysis was
performed using the Wilcoxon t-test. Data are expressed as median with interquartile range.
p < 0.0001, Table S1], and corresponding levels of tacrolimus
and secreted IFN-γ showed an inverse correlation (r = −0.23,
p= 0.037).
In addition, IFN-γ secretion-levels of 36 renal transplant-
recipients were monitored longitudinally before as well as one,
three, 6 and 12 months after transplantation. Demographic
and clinical characteristics as well as immunosuppressive drug
dosages and tacrolimus trough levels are shown in Table 1. In
line with highest levels of immunosuppressive drugs in the first
weeks after transplantation, IFN-γ levels were lowest after 1
month and increased again upon tapering of immunosuppressive
drugs to reach pre-transplant levels in after 12 months (p
< 0.0001, Figure 5B). Accordingly, corresponding tacrolimus
through levels were highest after 1 month and significantly lower
thereafter (Table 1, p < 0.0001).
Finally, we analyzed whether a single test result was able
to predict subsequent infectious episodes. At each time point,
the IFN-γ level in each transplant-recipient was associated with
infectious episodes in the subsequent time interval. Patients had
bacterial and viral infections, whereas no episodes of invasive
fungal infection occurred (Table 1). As shown in Figure 5C,
IFN-γ levels prior to transplantation were significantly higher
in patients with infections in the first month. In contrast,
IFN-γ levels at later time points tended to be lower in
patients with subsequent infection, although this did not
reach statistical significance. When infections were stratified
for bacterial and viral infections, IFN-γ levels 3 months
after transplantation were lower in patients with subsequent
bacterial infections (Figure S2). Likewise, IFN-γ levels 6 months
after transplantation were significantly lower in patients with
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FIGURE 5 | Association of IFN-γ secretion-levels with immunodeficiency and infectious episodes. (A) Whole blood samples of 51 healthy individuals, 71 hemodialysis
patients, 44 short term and 61 long-term transplant-recipients were stimulated with the lyosphere, and IFN-γ was determined from the supernatants. Median levels of
IFN-γ are indicated as bold line for each group. Statistical analysis was performed using the Kruskall Wallis test with Dunn’s post-test. (B) Whole blood samples of 36
renal transplant-recipients were collected before, as well as 1, 3, 6, and 12 months after transplantation. Samples were stimulated with the lyosphere, and IFN-γ was
determined from the supernatants. ELISA analysis was missing in two out of 36 patients. Statistical analysis was performed using the Friedman test. (C) Episodes of
(Continued)
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FIGURE 5 | bacterial and viral infections were recorded in the 36 renal transplant-recipients throughout the first year after transplantation. IFN-γ secretion-levels
before as well as 1, 3, and 6 months after transplantation were stratified according to whether patients underwent a subsequent episode of infection. Statistical
analysis was performed using the Mann-Whitney test. **p < 0.01; ***p < 0.001.
subsequent CMV infection episodes, which largely included
primary infections after a three month prophylaxis in D+/R-
patients. In contrast, IFN-γ levels at earlier time points did
not differ in patients with and without infections (Figure S2).
Overall, this indicated that IFN-γ levels were unable to predict
infection episodes on an individual basis.
DISCUSSION
Occurrence of adverse events after transplantation such as
infections and rejection episodes critically depend on the net state
of immunosuppression of the individual patient. Biomarkers
to analyze over- or underimmunosuppression in transplant-
recipients are not available. In this study, the utility of the
QuantiFERON monitor assay was characterized as a tool to
quantify the effect of immunosuppressive drugs on innate
and adaptive cellular immune function. Of note, cell-reactivity
showed diurnal variations that correlated with endogenous
cortisol levels in the absence of iatrogenic immunosuppression.
In addition, individual immunosuppressive drugs applied in vitro
had a dose-dependent decreasing effect on cell-reactivity which
was further enhanced when drugs were used in combination.
In line with previous observations (18), polyclonal immune
function showed a larger interindividual variability. While intra-
assay variability was very low, inter-assay reactivity varied
considerably over time. This not only held true for clinically
stable dialysis patients and long-term transplant-recipients but
also for immunocompetent controls with no apparent underlying
disease or intercurrent infection. Finally, cell-reactivity was
lowest in patients with highest levels of immunosuppressive
drugs whichwas shown both in cross-sectional analyses of patient
groups with different levels of immunodeficiency as well as in
renal transplant-recipients who were analyzed before and during
the first year after transplantation. Despite this strong association
of cell reactivity with overall immunosuppression in the various
groups, the assay seems of limited utility to individualize dosage
of immunosuppression or to predict infectious episodes on an
individual basis.
The stimulus used in the QuantiFERON monitor assay
comprises an anti-CD3 antibody for polyclonal stimulation of
T-cells and a TLR7/8 agonist that triggers components of the
innate immune response. This allows polyclonal stimulation of
blood samples and elicited a strong immune response in CD4
and CD8 T-cells as well as in NK-cells, whereas B-cells remained
unresponsive. Among a variety of cytokines tested, IFN-γ was
predominantly secreted, and therefore best suited as readout
for reactivity of immune cells. Although the overall number of
NK-cells was generally lower than that of CD4 or CD8 T-cells
(data not shown), the absolute number of IFN-γ secreting cells
was comparable for all three lymphocyte subpopulation. Thus,
our results show that NK-cells make a similar contribution to
IFN-γ secretion in this assay as CD4 and CD8 T-cells. Among
NK-cells, IFN-γ is known to be predominantly secreted by the
CD56bright subset (19). Apart from a direct induction by the
TLR agonist, IFN-γ secretion from NK-cells may also have been
indirectly amplified by stimulation-induced T-cell cytokines such
as IL-2 (20).
We found that IFN-γ levels were lower in dialysis
patients than in controls which may be related to uremic
immunodeficiency (21). In transplant recipients, the effects of
immunosuppressive drugs present in the plasma of patients
in vivo or of drugs added in vitro can be studied in clinically
relevant dosages, as the stimulus is directly added to whole blood.
Of note, the assay is very sensitive toward immunosuppressive
substances, as even diurnal variations in endogenous cortisol
levels inversely correlated with IFN-γ levels in the absence of
iatrogenic immunosuppressive drugs, which is important to
consider when interpreting test results for use in clinical practice.
It would have been informative to study the effect of individual
immunosuppressive drugs such as calcineurin inhibitors on
cellular immune function by comparing areas under the curve
(AUC) for IFN-γ and individual drugs. However, as we did
not have patients on drug monotherapy, we chose to perform
an in vitro stimulation of blood samples in the presence of
clinically relevant drug concentrations. This led to a dose-
dependent decrease in IFN-γ secretion, and combined action
of steroids and calcineurin inhibitors led to a further decrease
in IFN-γ production. Similar results were observed using a
flow-cytometric assay after 6 h stimulation (7, 17). Moreover,
our observations in vitro are compatible with results in patients
on a routine immunosuppressive drug regimen that included
basiliximab, calcineurin inhibitors (largely tacrolimus) and
steroids, as IFN-γ secretion was lowest in periods of highest drug
levels early after transplantation. This is conceivable for T-cells,
as steroids interfere with cytokine induction by suppressing
general immune function, and calcineurin inhibitors act by
inhibiting the phosphatase activity of calcineurin in T-cells
(22). In addition, calcineurin inhibitors were also shown to
dose-dependently inhibit IFN-γ secretion from NK-cells (20).
More drastic effects on measurable IFN-γ seem to act after
T-cell depleting therapy, as ATG treatment was shown to be
associated with a further decrease in IFN-γ secretion due
to an overall depletion of cytokine-producing cells (12, 23).
Despite the clear dose-dependent effect of individual drugs in
vitro, IFN-γ secretion and tacrolimus trough levels of patients
in vivo only showed a poor correlation. This is in line with
findings from previous studies (7, 12, 13) and emphasizes the
fact that the net inhibition of IFN-γ in patient samples is the
result of the inhibitory action of several immunosuppressive
drugs. Of note, in long-term transplant recipients, IFN-γ
secretion levels are similar to patients prior to transplantation
which indicates that tapering of immunosuppressive
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TABLE 1 | Characteristics of renal transplant-recipients analyzed before and within the first year after transplantation.
n (%) 36
Years of age (mean ± SD) 52.8 ± 15.5
Females n (%) 12 (33.3%)
UNDERLYING DISEASE
Glomerulonephritis 17 (47.2%)
Polycystic kidney disease 5 (13.9%)
Vascular/hypertensive nephropathy 5 (13.9%)
Diabetes mellitus I or II 2 (5.6%)
Tubulointerstitial nephritis 2 (5.6%)
Unknown/other 5 (13.9%)
Years of renal replacement therapy (mean ± SD) 4.8 ± 3.9








CMV serostatusa donor (D)/recipient (R) n (%) D–/R– 5 (16.7%) (0 infectious episodes)
D+/R– 8 (25.0%) (6 primary infections)
D–/R+ 10 (22.2%) (4 reactivations)
D+/R+ 13 (36.1%) (3 reactivations)
Immunosuppression Initial Month 1 Month 3 Month 6 Month 12b
Tacrolimus/cyclosporine A 36/0 (100/0%) 33/1 (91.7/2.8%) 32/2 (88.9/5.6%) 32/3 (88.9/8.3%) 28/4 (77.8/11.1%)
mTOR inhibitor 0 (0%) 2 (5.6%) 2 (5.6%) 1 (2.8%) 3 (8.3%)
Methylprednisolone 36 (100%) 36 (100%) 36 (100%) 36 (100%) 35 (97.2%)
Mycophenolate mofetil 36 (100%) 36 (100%) 36 (100%) 36 (100%) 35 (97.2%)
Basiliximab 35 (97.2%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Rituximab 2 (5.6%)c 0 (0%) 1 (2.8%)d 0 (0%) 0 (0%)
Antithymocyte globulin 1 (2.8%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Tacrolimus levels (ng/mL)e
Median (IQR)
n.d. 8.5 (7.0–10.8) 7.2 (5.9–8.1) 6.6 (5.6–7.7) 6.2 (4.7–7.0)
Methylprednisolone
(mg/d)e Median (IQR)
n.a. 12 (8-12) 4 4 4
Infections Month 0 to ≤1 Month 1 to ≤3 Month 3 to ≤6 Month 6 to ≤12
Infectious episodesf 10 in 8 patients (9
viral, 1 bacterial)
21 in 16 patients (17
viral, 4 bacterial)
20 in 18 patients (16
viral, 4 bacterial)
30 in 19 patients (19
viral, 11 bacterial)
Opportunistic infectionsg 9 in 7 patients 16 in 13 patients 16 in 16 patients 17 in 16 patients
aR+ patients received preemptive therapy, D+/R- received 3 months of valganciclovir prophylaxis.
bTwo patients had missing ELISA results in the QuantiFERON monitor test at month 12.
cAB0-incompatible transplantations.
dAntibody-mediated rejection episode.
eRefers to actual trough levels/dosage at the time of analysis.
fViral and bacterial infections, no invasive fungal infections occurred.
gBKPyV, CMV, EBV, Hepatitis B, HSV, influenza, VZV, Pneumocystis jirovecii; MM, mismatch; mTOR, mammalian target of rapamycin; SD, standard deviation; IQR, interquartile range.
drugs allow restoration of cellular immune function in
the long-term.
In general, low counts of lymphocytes including CD4 T-
cells or NK-cells have been associated with adverse events
after transplantation such as increased infections and rejection
episodes (24, 25). Based on this observation, one may argue that
the lowest levels in IFN-γ secretion in the early periods after
transplantation may be the result of a relative lymphopenia in
this time period. As described above, an association between low
lymphocyte counts and IFN-γ secretion was indeed observed in
patients after T-cell depleting antibody therapy (12). However,
in our patient population where only one patient received T-cell
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depleting antibodies, IFN-γ levels did not directly correlate with
lymphocyte counts. In this situation, assessment of antigen-
specific cell functionality may better reflect the individual
risk than lymphopenia. This was observed for specific T-cells
toward pathogens such as CMV or VZV, where a decrease
in the functionality of virus-specific T-cells was more strongly
associated with impaired pathogen control than a decrease in
T-cell or lymphocyte numbers in general (26). Apart from
T-cells, this also seems to hold true for NK-cells. Targeting
NK-cell function in a bioassay seems interesting in light of
the recent findings that impaired NK-cell function was shown
to be superior to predict development of NK-cell dependent
infections in transplant-recipients as opposed to quantifying
NK-cell numbers (25).
A generalized immune function assay is increasingly discussed
as potential tool to monitor immunosuppression or to predict
infectious complications of any type. Unfortunately, the clinical
utility to monitor under- or overimmunosuppression based
on a single test result seems rather limited. This also holds
true for prediction of infections on an individual basis,
which may primarily be related to the different impacts of
immunosuppression on the various types of infections and their
clinical manifestations, or on multifactorial effects in case of
infections with BKPyV. In addition, cellular immune function
can vary considerably over time even in individuals without
any clinically apparent disease or infection. This not only holds
true for dialysis patients and transplant-recipients, but also for
immunocompetent controls. These observations may suggest
that cellular immune function is critically influenced even by
subtle variations in the individual health status, which deserves
further study. It is interesting to note that pre-transplant IFN-γ
secretion was significantly higher in patients with infections in
the first month as compared to patients without infections. This
may suggest that this group of patients requires particularly high
numbers of functional cells to control infections at steady state. If
these patients receive immunosuppression, susceptibility toward
infections may be extraordinarily high. In the post-transplant
setting, IFN-γ levels 1 month after transplantation had limited
ability to predict individual infection events, as cellular immune
function was generally low in all patients. In contrast, at later
time points, when immunosuppressive drug dosage was already
tapered and antimicrobial prophylaxis largely discontinued,
sustained low levels of IFN-γ may indicate failure to reconstitute
sufficient immunity and may therefore be a better predictor
for subsequent infections. Indeed, the difference in IFN-γ levels
between patients with and without subsequent bacterial and
CMV infections was highest at 3–6 months after transplantation,
although the overall number of patients with infections was
expectedly low at later time points after transplantation. Similar
results were reported in a Canadian study among transplant-
recipients (12, 23), where most pronounced associations of IFN-
γ levels with subsequent infection episodes were reported at
month 6 after transplantation. Interestingly, in liver-transplant-
recipients, IFN-γ secretion 1 week after transplantation had
the best ability to predict subsequent infection or rejection
events (15). However, as with our study, variability in IFN-γ
secretion-levels in all groups with and without infections was
rather high which decreases the diagnostic value to predict
infections on an individual basis. Likewise, other tests to directly
or indirectly evaluate the net state of immunosuppression such
as the Cylex Immuknow assay or analysis of viral DNA (Torque
teno virus or Epstein Barr virus) have shown associations with
infectious episodes, but also suffered from limited predictive
capacity for use in clinical practice (27–29).
Our study has limitations. First, only one rejection episode
occurred, which precluded assessment to predict rejection.
Secondly, the sample size of our longitudinal cohort of 36
patients may be too low to reveal clear associations of immune
function with infectious episodes and to define thresholds.
Nevertheless, even at time points where differences in IFN-γ
levels between patients with and without subsequent infections
were most pronounced, prediction was poor based on an
individual test result.
In conclusion, the QuantiFERON monitor assay elicits a
robust IFN-γ response among T-cell subpopulations and NK-
cells. As it can be applied directly from whole blood, it is
suited to characterize a dose-dependent inhibitory action of
individual immunosuppressive drugs or their combinations
in clinically relevant concentrations, and may therefore be
interesting for basic research on pharmacodynamic activity of
immunosuppressive drugs. Although low levels of IFN-γ were
associated with increased susceptibility toward infections in large
cohorts of patients, this general immune function assay did
not prove valuable to predict infections on an individual basis.
Therefore, more specific assays relying on pathogen-specific
T-cell stimulation may hold better promise as a personalized
approach to predict infection episodes (10, 26).
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